Latest Algeta ASA Stories
LONDON, March 26, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
OSLO, Norway, June 6, 2011 /PRNewswire-FirstCall/ -- - Trial Stopped Based on Data Results from Pre-Planned Interim Analysis; Patients in Placebo Arm Will Be Offered Treatment with Radium-223 Chloride Algeta ASA (OSE: ALGETA) today announced that the Phase III ALSYMPCA (radium-223 chloride in SYMptomatic Prostate CAncer) trial evaluating the investigational compound radium-223 chloride, which is exclusively licensed by Bayer, in patients with castration-resistant prostate cancer...
WAYNE, N.J., June 6, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
RICHMOND, Calif., Oct.
OSLO, December 11 /PRNewswire-FirstCall/ -- Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton. The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study is a double-blind,...
OSLO, September 3 /PRNewswire-FirstCall/ -- - Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial...
OSLO, Norway, February 3 /PRNewswire-FirstCall/ -- - ALSYMPCA Study Designed to Evaluate Alpharadin for the Treatment of Bone Metastases in Prostate Cancer Patients Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that it is to enroll US patients into its ALSYMPCA phase III trial evaluating Alpharadin as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC).
- In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
- In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.